Medtronic Lays Out Plans To Achieve 5%+ Annual Growth
The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.
You may also be interested in...
Medtech Insight sat down with Nina Goodheart, the president of Medtronic’s structural heart and aortic operating unit, to learn more about her experience with the company during the pandemic, the company’s commitment to diversity and inclusion, and the future of structural heart technology.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.
The new independent kidney-care company will be equally co-owned by both companies. It will include all of Medtronic’s renal care solutions business, including renal access, acute therapies, and chronic therapies.